Literature DB >> 10378618

A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment.

S M McDonnell1, B L Preston, S A Jewell, J C Barton, C Q Edwards, P C Adams, R Yip.   

Abstract

PURPOSE: Hemochromatosis is a genetic disorder of iron absorption that affects 5 per 1,000 persons and is associated with reduced health and quality of life. We sought to determine the type and frequency of symptoms that patients experienced before the diagnosis and the treatments that they received.
METHODS: We mailed a questionnaire to 3,562 patients with hemochromatosis who were located using patient advocacy groups, physicians, blood centers, newsletters, and the Internet.
RESULTS: Of the 2,851 respondents, 99% were white and 62% were men. Circumstances that led to diagnosis of hemochromatosis included symptoms (35%), an abnormal laboratory test (45%), and diagnosis of a family member with hemochromatosis (20%). The mean (+/- SD) age of symptom onset was 41 +/- 14 years. Symptoms had been present for an average of 10 +/- 10 years before the diagnosis was made. Among the 58% of patients with symptoms, 65% had physician-diagnosed arthritis and 52% had liver disease. The most common and troublesome symptoms were extreme fatigue (46%), arthralgia (44%), and loss of libido (26%). Physician instructions to patients included treatment with phlebotomy (90%), testing family members (75%), and avoiding iron supplements (65%).
CONCLUSIONS: The diagnosis of hemochromatosis in most patients was delayed. Physician education is needed to increase the detection of patients with the disease and to improve its management.

Entities:  

Mesh:

Year:  1999        PMID: 10378618     DOI: 10.1016/s0002-9343(99)00120-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

1.  Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled.

Authors:  J E Haddow; L A Bradley
Journal:  BMJ       Date:  1999-08-28

Review 2.  Controversy in primary care: Should asymptomatic haemochromatosis be treated?

Authors:  C J Seamark; M Hutchinson
Journal:  BMJ       Date:  2000-05-13

3.  Hereditary haemochromatosis: never seen a case?

Authors:  J Emery; P Rose
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

4.  The case for strengthening education and training for general practice.

Authors:  T van Zwanenberg; M Pringle; S Smail; M Baker; S Field
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

5.  Penetrance of haemochromatosis.

Authors:  E Beutler
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 6.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

7.  A patient with a rare cause of elevated troponin I.

Authors:  Antonios Kilias; Karin Klingel; Meinrad Gawaz; Ulrich Kramer; Peter Seizer
Journal:  Clin Res Cardiol       Date:  2015-04-28       Impact factor: 5.460

Review 8.  Hereditary hemochromatosis: a neglected diagnosis in orthopedics: a series of 7 patients with ankle arthritis, and a review of the literature.

Authors:  Ake Carlsson
Journal:  Acta Orthop       Date:  2009-06       Impact factor: 3.717

9.  Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study.

Authors:  Ronald T Acton; James C Barton; Leah V Passmore; Paul C Adams; Gordon D McLaren; Catherine Leiendecker-Foster; Mark R Speechley; Emily L Harris; Oswaldo Castro; Jacob A Reiss; Beverly M Snively; Barbara W Harrison; Christine E McLaren
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06-27       Impact factor: 11.382

10.  Compound heterozygote (C282Y/H63D) of hereditary hemochromatosis in a 16-year-old girl with hypoplastic kidney.

Authors:  Barbara Kaczorowska-Hac; Katarzyna Sikorska; Krzysztof P Bielawski; Krystyna Schramm; Anna Balcerska
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.